Klogene Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Klogene Therapeutics, Inc.
Canaan Partners-backed biotech will investigate the therapeutic potential of three-way junctions in folded RNA. UC Berkeley and Duke sign separate license agreements related to CRISPR gene-editing technology.
Recent executive-level company changes and promotions in the biopharma, medical device, and diagnostics industries.
Two Western big pharmas struck back-to-back deals this week with two U.S. biopharmas and will bring their innovative drugs to Asia without a local partner. The details of the deals are different, but both signal a willingness on the part of biopharmas to partner with experienced, feet-on-the-ground Western companies as a route into emerging Asian markets, though they’ll still need to find a local partner down the road.
Start-Up's monthly comprehensive review of emerging life science companies that have received venture funding during the month, including companies in the pharmaceutical, medical device, diagnostic and research instrumentation and reagent sectors.
- Drug Delivery
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
- Kogenix Therapeutics, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.